ALKS vs CRL: fair value comparison
Alkermes plc and Charles River Laboratories International, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CRL currently sits closer to the top of our discount ranking. ALKS carries the stronger quality grade.
| ALKS | CRL | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $49.53 | $291.50 |
| 12-month range | $28.26–$51.72 | $161.25–$232.51 |
| Sector rank | #113 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | A | C |
| Momentum grade | C | — |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ALKS fair value analysis · CRL fair value analysis